OPT-302

· Opthea Limited

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for OPT-302, covering 2017-11-06 to 2025-08-05. Get the full timeline:

Most recent: Clinical Trial Update: OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) [Phase 3]